Insider Selling: Teladoc Health, Inc. (NYSE:TDOC) Insider Sells $13,210.00 in Stock

Teladoc Health, Inc. (NYSE:TDOC) insider Daniel Trencher sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $13.21, for a total transaction of $13,210.00. Following the completion of the sale, the insider now directly owns 26,192 shares of the company’s stock, valued at approximately $345,996.32. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Daniel Trencher also recently made the following trade(s):

• On Monday, March 18th, Daniel Trencher sold 1,000 shares of Teladoc Health stock. The stock was sold at an average price of $15.18, for a total transaction of $15,180.00.
• On Monday, March 4th, Daniel Trencher sold 6,780 shares of Teladoc Health stock. The shares were sold at an average price of $14.52, for a total transaction of $98,445.60.
• On Tuesday, February 20th, Daniel Trencher sold 1,000 shares of Teladoc Health stock. The shares were sold at an average price of $20.64, for a total transaction of $20,640.00.

Teladoc Health Stock Performance

NYSE:TDOC opened at $12.99 on Friday. Teladoc Health, Inc. has a 1-year low of $12.85 and a 1-year high of $30.41. The company’s fifty day moving average price is $15.59 and its 200-day moving average price is $17.91. The company has a current ratio of 3.54, a quick ratio of 3.47 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Tuesday, February 20th. The health services provider reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05. The firm had revenue of $660.50 million for the quarter, compared to analyst estimates of $670.79 million. Teladoc Health had a negative net margin of 8.47% and a negative return on equity of 9.22%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.23) earnings per share. As a group, analysts anticipate that Teladoc Health, Inc. will post -1.07 EPS for the current year.

Institutional Trading of Teladoc Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TDOC. Dimensional Fund Advisors LP grew its position in Teladoc Health by 116.7% during the first quarter. Dimensional Fund Advisors LP now owns 3,593,819 shares of the health services provider’s stock valued at $93,070,000 after buying an additional 1,935,496 shares during the period. Vanguard Group Inc. grew its position in Teladoc Health by 11.8% during the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after buying an additional 1,855,480 shares during the period. Norges Bank acquired a new stake in Teladoc Health during the fourth quarter valued at $34,632,000. Point72 Asset Management L.P. acquired a new stake in Teladoc Health during the fourth quarter valued at $31,398,000. Finally, Two Sigma Investments LP grew its position in Teladoc Health by 68.6% during the first quarter. Two Sigma Investments LP now owns 3,191,291 shares of the health services provider’s stock valued at $82,654,000 after buying an additional 1,298,934 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on TDOC shares. Royal Bank of Canada decreased their target price on shares of Teladoc Health from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, February 21st. Piper Sandler decreased their target price on shares of Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, February 21st. Leerink Partnrs reissued a “market perform” rating on shares of Teladoc Health in a research report on Monday, February 26th. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research report on Friday, April 5th. Finally, DA Davidson decreased their target price on shares of Teladoc Health from $22.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, February 21st. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $22.23.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.